Efficacy and Safety of Topical Tranexamic Acid Alone or in Combination with Either Fractional Carbon Dioxide Laser or Microneedling for the Treatment of Melasma
Keywords:
Tranexamic Acid, Carbon Dioxide Laser, Microneedling, MelasmaAbstract
Introduction: Tranexamic acid (TXA) is a promising treatment modality for melasma. Microneedling (MN) and fractional carbon dioxide (CO2) laser were reported to enhance TXA transepidermal delivery.
Objectives: To compare efficacy and safety of topical TXA alone or in combination with either fractional CO2 laser or MN for treatment of melasma.
Methods: Thirty females with facial melasma were divided randomly into 3 equal groups after excluding pregnant and lactating women and those using oral contraceptives or other hormonal therapy. Patients of group A were treated with fractional CO2 laser and those of group B were treated with MN (4 sessions, 3 weeks apart for both) with immediate topical application of TXA 5% solution after sessions and daily application of 5% TXA cream for both groups. Patients of group C were treated by topical daily application of TXA 5% cream. Evaluation was done by modified melasma area and severity index scores (mMASI), patient satisfaction and dermoscopy.
Results: Statistically significant improvement of mMASI was reported in all studied groups with a significantly better improvement in patients of groups A and B than those of group C, meanwhile the difference between groups A and B was statistically insignificant.
Conclusions: Topical TXA is a safe and fairly effective treatment modality for facial melasma. Combining TXA with either fractional CO2 laser or MN yielded significantly better improvement than when used alone. Fractional CO2 laser carries the risk of post-inflammatory hyperpigmentation in patients with skin types III and IV and requires meticulous patient selection.
References
Handel AC, Miot LDB, Miot HA. Melasma. A clinical and epidemiological review. An Bras Dermatol.. 2014;89(5):771-782. DOI: 10.1590/abd1806-4841.20143063. PMID: 25184917. PMCID: PMC4155956.
Freitag FM, Cestari TF, Leopoldo LR, Paludo P, Boza JC. Effect of melisma on quality of life in a sample of women living in Southern Brazil. J Eur Acad Dermatol Venereol. 2008;22(6):655-662. DOI: 10.1111/j.1468-3083.2007.02472.x. PMID: 18410339.
Polnikorn N. Treatment of refractory melasma with the Med Lite C6 Q-switched Nd. YAG laser and alpha arbutin. a prospective study. J Cosmet Laser Ther. 2010;12(3):126-131. DOI: 10.3109/14764172.2010.487910. PMID: 20482238.
Cheng L, Pettersen D, Ohlsson B, et al. Discovery of the fibrinolysis inhibitor AZD 6564, acting via interference of a protein–protein interaction. ACS Med Chem Lett. 2014;18(5):538-543. DOI: 10.1021/ml400526d. PMID: 24900876. PMCID: PMC4027757.
Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing, non-ablative, fractional, and ablative laser resurfacing. J Am Acad Dermatol. 2008;58(5):719-737. DOI: 10.1016/j.jaad.2008.01.003. PMID: 18423256.
Tuan-MahmoodTM, McCrudden MT, Torrisi BM, et al. Microneedles for intradermal and transdermal drug delivery. Eur J Pharm Sci. 2013;50(5):623-637. DOI: 10.1016/j.ejps.2013.05.005. PMID: 23680534. PMCID: PMC4119996.
Alegre-Sánchez A, Jiménez-Gómez N, Boixeda P. Laser-assisted drug delivery. Actas Dermosifiliogr. 2018;109(10):858-867. DOI: 10.1016/j.ad.2018.07.008. PMID: 30266385.
Shende P, Sardesai M, Gaud RS. Micro to nanoneedles. A trend of modernized transepidermal drug delivery system. Artif Cells Nanomed Biotechnol. 2018;46(1):19-25. DOI: 10.1080/21691401.2017.1304409. PMID: 28355887.
Qu Y, Wang F, Liu J, Xia X. Clinical observation and dermoscopy evaluation of fractional CO2 laser combined with topical tranexamic acid in melasma treatments. J Cosmet Dermatol. 2021;20(4):1110-1116. DOI: 10.1111/jocd.13992. PMID: 33565243.
Mekawy KMM, Sadek A, Seddeik Abdel-Hameed AK. Micro-needling versus fractional carbon dioxide laser for delivery of tranexamic acid in the treatment of melasma: A split-face study. J Cosmet Dermatol. 2021;20(2):460-465. DOI: 10.1111/jocd.13537. PMID: 32562337.
Neeley MR, Pearce FB, Collawn SS. Successful treatment of malar dermal melasma with a fractional ablative CO₂ laser in a patient with type V skin. J Cosmet Laser Ther. 2010;12(6):258-260. DOI: 10.3109/14764172.2010.538412. PMID: 21142733.
Kim HJ, Moon SH, Cho SH, Lee JD, Kim HS. Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review. Acta Derm Venereol. 2017;97(7):776-781. DOI: 10.2340/00015555-2668. PMID: 28374042.
Trelles MA, Velez M, Gold MH. The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two: a comparative study. J Drugs Dermatol. 2010;9(4):315-322. PMID: 20514787.
El-Sinbawy ZG, Abdelnabi NM, Sarhan NE, Elgarhy LH. Clinical & ultrastructural evaluation of the effect of fractional CO2 laser on facial melasma. Ultrastruct Pathol. 2019;43(4-5):135-144. DOI: 10.1080/01913123.2019.1673861. PMID: 31575311.
Tawfic SO, Abdel Halim DM, Albarbary A, Abdelhady M. Assessment of combined fractional CO2 and tranexamic acid in melasma treatment. Lasers Surg Med. 2019;51(1):27-33. DOI: 10.1002/lsm.23032. PMID: 30431171.
Esmat S, Z Elramly A, Shahin D, Hilal RF. Combining Low Power Fractional CO2 With QS-NdYAG Toning in the Treatment of Melasma Reduces the Incidence of Punctate Leukoderma. Lasers Surg Med. 2021;53(10):1325-1340. DOI: 10.1002/lsm.23441. PMID: 34164829.
Nourmohammadi Abadchi S, Fatemi Naeini F, Beheshtian E. Combination of Hydroquinone and Fractional CO2 Laser versus Hydroquinone Monotherapy in Melasma Treatment: A Randomized, Single-blinded, Split-face Clinical Trial. Indian J Dermatol. 2019;64(2):129-135. DOI: 10.4103/ijd.IJD_240_17. PMID: 30983609. PMCID: PMC6440181.
Hsiao F, Lin YC, Huang CC. Efficacy and safety of a single treatment using a 10,600-nm carbon dioxide fractional laser for mild-to-moderate atrophic acne scars in Asian skin. Dermatologica Sinica. 2013;31(2):59-63. DOI: 10.1016/j.dsi.2012.09.009.
Delgado RE, Torre Mde L. Use of fractional laser in mixed-race patients. Facial Plast Surg. 2013;29(3):161-166. DOI: 10.1055/s-0033-1347006. PMID: 23761119.
Lima Ede A. Microneedling in facial recalcitrant melasma: report of a series of 22 cases. An Bras Dermatol. 2015;90(6):919-921. DOI: 10.1590/abd1806-4841.20154748. PMID: 26734882. PMCID: PMC4689089.
Xu Y, Ma R, Juliandri J, et al. Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma: A randomized, self-controlled, split-face study. Medicine (Baltimore). 2017;96(19):e6897. DOI: 10.1097/MD.0000000000006897. PMID: 28489798. PMCID: PMC5428632.
Wu SZ, Muddasani S, Alam M. A Systematic Review of the Efficacy and Safety of Microneedling in the Treatment of Melasma. Dermatol Surg. 2020;46(12):1636-1641. DOI: 10.1097/DSS.0000000000002763. PMID: 32897944.
Menon A, Eram H, Kamath PR, Goel S, Babu AM. A Split Face Comparative Study of Safety and Efficacy of Microneedling with Tranexamic Acid versus Microneedling with Vitamin C in the Treatment of Melasma. Indian Dermatol Online J. 2019;11(1):41-45. DOI: 10.4103/idoj.IDOJ_22_19. PMID: 32055507. PMCID: PMC7001392.
Saleh FY, Abdel-Azim ES, Ragaie MH, Guendy MG. Topical tranexamic acid with microneedling versus microneedling alone in treatment of melasma. Clinical, histopathologic, and immunohistochemical study. J Egypt Womens Dermatol Soc. 2019;16(2):89-96. DOI: 10.4103/JEWD.JEWD_25_19.
Farshi S, Mansouri P. Study of efficacy of microneedling and mesoneedling in the treatment of epidermal melasma: A pilot trial. J Cosmet Dermatol. 2020;19(5):1093-1098. DOI: 10.1111/jocd.13369. PMID: 32196865.
Steiner D, Feola C, Bialeski N. Study evaluating the efficacy of topical and injected tranexamic acid in treatment of melasma. Surg Cosmet Dermatol. 2009;1(4):174–177.
Ebrahimi B, Naeini FF. Topical tranexamic acid as a promising treatment for melasma. J Res Med Sci. 2014;19(8):753-757. PMID: 25422661. PMCID: PMC4235096.
Kanechorn Na Ayuthaya P, Niumphradit N, Manosroi A, Nakakes A. Topical 5% tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial. J Cosmet Laser Ther. 2012;14(3):150-154. DOI: 10.3109/14764172.2012.685478. PMID: 22506692.
Banihashemi M, Zabolinejad N, Jaafari MR, Salehi M, Jabari A. Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma. J Cosmet Dermatol. 2015;14(3):174-177. DOI: 10.1111/jocd.12152. PMID: 26177992.
Kaleem S, Ghafoor R, Khan S. Comparison of efficacy of Tranexamic Acid Mesotherapy versus 0.9% normal Saline for Melasma; A split face study in a Tertiary Care Hospital of Karachi. Pak J Med Sci. 2020;36(5):930-934. DOI: 10.12669/pjms.36.5.2379. PMID: 32704266. PMCID: PMC7372652.
Tse TW, Hui E. Tranexamic acid: an important adjuvant in the treatment of melasma. J Cosmet Dermatol. 2013;12(1):57-66. DOI: 10.1111/jocd.12026. PMID: 23438143.
Ng SP, Marcant M, Davis AF. In vitro human skin concentrations following topical application of 2% tranexamic acid in co-enhancer cream and branded cream formulations. J Cosmet Dermatol. 2020;19(10):2656-2662. DOI: 10.1111/jocd.13301. PMID: 31961048.
Arora P, Sarkar R, Garg VK, Arya L. Lasers for treatment of melasma and post-inflammatory hyperpigmentation. J Cutan Aesthet Surg. 2012;5(2):93-103. DOI: 10.4103/0974-2077.99436. PMID: 23060704. PMCID: PMC3461803.
Lueangarun S, Sirithanabadeekul P, Wongwicharn P, et al. Intradermal Tranexamic Acid Injection for the Treatment of Melasma: A Pilot Study with 48-week Follow-up. J Clin Aesthet Dermatol. 2020;13(8):36-39. PMID: 33178380. PMCID: PMC7595366.
Trivedi MK, Yang FC, Cho BK. A review of laser and light therapy in melasma. Int J Womens Dermatol. 2017;3(1):11-20. DOI: 10.1016/j.ijwd.2017.01.004. PMID: 2849204.; PMCID: PMC5418955.
Published
Issue
Section
License
Copyright (c) 2023 Safaa Mamdouh Kamal , Doaa Hegab, Gamal Mohamed El Maghraby, Amal Ahmad El- Ashmawy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
